Pharmacological Inhibition of CB1Cannabinoid Receptor Protects Against Doxorubicin-Induced Cardiotoxicity
Top Cited Papers
- 23 July 2007
- journal article
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 50 (6) , 528-536
- https://doi.org/10.1016/j.jacc.2007.03.057
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Nitric Oxide and Peroxynitrite in Health and DiseasePhysiological Reviews, 2007
- The Endocannabinoid System as an Emerging Target of PharmacotherapyPharmacological Reviews, 2006
- Thrombopoietin Protects Against In Vitro and In Vivo Cardiotoxicity Induced by DoxorubicinCirculation, 2006
- Modulation of Doxorubicin-Induced Cardiac Dysfunction in Toll-Like Receptor-2–Knockout MiceCirculation, 2004
- Cyclooxygenase-2 Inhibitor Treatment Improves Left Ventricular Function and Mortality in a Murine Model of Doxorubicin-Induced Heart FailureCirculation, 2004
- Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMNJournal of Leukocyte Biology, 2003
- CB1 cannabinoid receptor antagonism promotes remodeling and cannabinoid treatment prevents endothelial dysfunction and hypotension in rats with myocardial infarctionBritish Journal of Pharmacology, 2003
- Adriamycin-induced Cardiomyocyte and Endothelial Cell Apoptosis: In Vitro and In Vivo StudiesJournal of Molecular and Cellular Cardiology, 2002
- Anthrazykline in der KrebstherapieDrugs, 1997
- Adriamycin: The Role of Lipid Peroxidation in Cardiac Toxicity and Tumor ResponseScience, 1977